Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript

Jul 30, 2020 • 04:30 pm ET

Previous

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Analyst
Christopher Raymond

COVID-related effects and also some going in the other direction. Can you talk about maybe any regional differences that you're seeing, positive or otherwise, in terms of your territories?

Executive
Andrew Oxtoby

Yes. Yes, certainly. So first of all, just to orient you, when we think about the country, we divide the country into 10 regions. So as we talked about, we have 80 practice account managers. They're divided up equally into 10 regions, so eight per region. So first of all, all 10 of those regions have patients who have started on PALFORZIA. So from that standpoint, we see that consistently across the country.

Now that said, as we've seen more and more patients go on the product, the first places we saw them go on were the South and Southeast, particularly Texas, Florida and Georgia. And what's happened is we're now seeing more and more patients come on in New England and New York, and we're seeing them start to pick up momentum. And I think it's easy to speculate that it would be -- that's really attributed to the incidents of COVID there currently and the fact that they're coming out of what was a heavier incidence rate a few months ago.

At this point, the vast majority of our account managers are able to engage with allergists, to some degree, face-to-face across the country. Many of them are in some sort of hybrid model where they're doing a mixture of face-to-face as well as virtual engagements using technology. The most challenging -- in terms of our ability to have face-to-face meetings, the most challenging area continues to be the Southwest, particularly around Los Angeles and the Inland Empire and to -- also, to a degree, in Arizona.

So there are some differences there, clearly. And that, I suspect, will continue to be the case. But what is encouraging is even in areas where there are more challenges because of COVID, we're still seeing patients go on the product, as allergists are working through how they're going to manage their practice given COVID. And maybe they're managing it at reduced capacity and have to do things so they can accommodate things like social distancing, but they're still persevering through that and working through the backlog of appointments that we talked about and looking to try and put patients on PALFORZIA where they can.

Analyst
Christopher Raymond

Thank you.

Operator
Operator

Thank you. Our next question comes from the line of Charles Duncan with Cantor Fitzgerald. Your line is open. Please go ahead.

Analyst
Charles C. Duncan

Good afternoon, Jayson and team. Yes, liked all the updates on progress working through a challenging environment. A couple of quick questions for all of you. First of all, for Andrew, it's nice to hear that you've got some patients that have been started on PALFORZIA. I guess I'm wondering if there's been any feedback from the field with regard to the early clinical experience and if that's consistent with what you had anticipated given the experience in the studies.

Executive
Andrew Oxtoby

Yes. Charles, it's